Foghorn Therapeutics to Present at Four Conferences in May.
PorAinvest
jueves, 22 de mayo de 2025, 7:06 am ET1 min de lectura
CWEN--
The Evercore Biotech Diamonds in the Rough Virtual Event will feature a fireside chat with Adrian Gottschalk on May 27, 2025, at 2:00 p.m. EDT [1]. The TD Cowen’s 6th Annual Oncology Innovation Summit will also host a fireside chat with Gottschalk on May 28, 2025, at 1:30 p.m. EDT. The Jefferies Global Healthcare Conference 2025, taking place in New York on June 5, 2025, at 3:45 p.m. EDT, will include a presentation by Gottschalk. Additionally, the Goldman Sachs 46th Annual Global Healthcare Conference 2025, scheduled for June 11, 2025, at 10:00 a.m. EDT in Miami, will feature a presentation by Gottschalk.
Foghorn Therapeutics focuses on oncology, leveraging its proprietary Gene Traffic Control® platform to develop a broad pipeline of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company aims to transform the lives of people suffering from a wide spectrum of diseases.
For more information on Foghorn Therapeutics and its upcoming events, please visit their website at www.foghorntx.com [2].
References:
[1] https://www.marketscreener.com/quote/stock/FOGHORN-THERAPEUTICS-INC-114282635/news/Foghorn-Therapeutics-to-Participate-in-Four-Upcoming-Investor-Conferences-50037145/
[2] https://www.foghorntx.com
FHTX--
TD--
TOI--
Foghorn Therapeutics, a clinical-stage biotech company, announced that management will participate in various upcoming conferences. These include the Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025, and Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company's focus is on oncology, with the potential to transform lives through its Gene Traffic Control platform and broad pipeline.
Cambridge, Mass., May 22, 2025 (GLOBE NEWSWIRE) — Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company specializing in gene expression correction, has announced its participation in several upcoming investor conferences. The company's management, led by President and CEO Adrian Gottschalk, will present at the Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen’s 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025, and Goldman Sachs 46th Annual Global Healthcare Conference 2025.The Evercore Biotech Diamonds in the Rough Virtual Event will feature a fireside chat with Adrian Gottschalk on May 27, 2025, at 2:00 p.m. EDT [1]. The TD Cowen’s 6th Annual Oncology Innovation Summit will also host a fireside chat with Gottschalk on May 28, 2025, at 1:30 p.m. EDT. The Jefferies Global Healthcare Conference 2025, taking place in New York on June 5, 2025, at 3:45 p.m. EDT, will include a presentation by Gottschalk. Additionally, the Goldman Sachs 46th Annual Global Healthcare Conference 2025, scheduled for June 11, 2025, at 10:00 a.m. EDT in Miami, will feature a presentation by Gottschalk.
Foghorn Therapeutics focuses on oncology, leveraging its proprietary Gene Traffic Control® platform to develop a broad pipeline of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company aims to transform the lives of people suffering from a wide spectrum of diseases.
For more information on Foghorn Therapeutics and its upcoming events, please visit their website at www.foghorntx.com [2].
References:
[1] https://www.marketscreener.com/quote/stock/FOGHORN-THERAPEUTICS-INC-114282635/news/Foghorn-Therapeutics-to-Participate-in-Four-Upcoming-Investor-Conferences-50037145/
[2] https://www.foghorntx.com
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios